CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
526 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
p38α inhibitor 9
CAS :p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.Formule :C27H24FN3O3Couleur et forme :SolidMasse moléculaire :457.496CDK2 degrader 6
CAS :CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.Formule :C23H22F5N5O3Couleur et forme :SolidMasse moléculaire :511.44INX-315
CAS :INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.Formule :C19H21N7O3SDegré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :427.48Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Formule :C12H8N4O2SCouleur et forme :SolidMasse moléculaire :272.28CDK5-IN-2
CAS :CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Formule :C29H28FN5OCouleur et forme :SolidMasse moléculaire :481.56CDK1-IN-5
CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.Formule :C27H26ClN5OSCouleur et forme :SolidMasse moléculaire :504.05Protein kinase inhibitor 13
CAS :Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Formule :C19H20FN5OSCouleur et forme :SolidMasse moléculaire :385.458CDK4/6-IN-3
CAS :CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.Formule :C25H31FN8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :462.57CDK9/PARP-IN-1
CAS :CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.Formule :C38H34F2N8O3Couleur et forme :SolidMasse moléculaire :688.725YKL-1-116
CAS :YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.Formule :C34H38N8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :606.72Protein Kinase Inhibitor 12
CAS :<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Formule :C14H14N4OSDegré de pureté :98.06%Couleur et forme :SolidMasse moléculaire :286.35Anticancer agent 30
<p>Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.</p>Formule :C22H15ClFNOCouleur et forme :SolidMasse moléculaire :363.81SGC-CLK-1
CAS :SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.Formule :C19H15F3N6O2Couleur et forme :SolidMasse moléculaire :416.36CDK2-IN-31
CAS :CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.Formule :C37H52N6O5Couleur et forme :SolidMasse moléculaire :660.85CDK12/13 ligand 1
CAS :ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.Formule :C26H26BrN5OCouleur et forme :SolidMasse moléculaire :504.42Tizolemide
CAS :Tizolemide, a sulfonamide diuretic compound with alkaline properties, is cleared through the tubular transport system. It induces changes in the passive transport components across the basolateral membrane of isolated frog skin.Formule :C11H14ClN3O3S2Couleur et forme :SolidMasse moléculaire :335.83DDO-6079
CAS :DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.Formule :C18H13ClN2O3Couleur et forme :SolidMasse moléculaire :340.76CDK7-IN-26
CAS :CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor with an IC50 of 7.4 nM. The compound effectively suppresses the growth of xenograft tumors derived from triple-negative breast cancer (TNBC) cell lines in vivo and has an IC50 of 0.15 μM for inhibiting MDA-MB-453 cells in vitro.Formule :C22H22FN6OPSMasse moléculaire :468.49CDK7-IN-18
CAS :CDK7-IN-18: potent, pyrimidine-based CDK7 inhibitor with cancer research potential.Formule :C22H24F3N7OSDegré de pureté :99.28%Couleur et forme :SolidMasse moléculaire :491.53CDK8-IN-14
CAS :<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Formule :C18H13N3O2Couleur et forme :SolidMasse moléculaire :303.31GFB-12811
CAS :GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Formule :C22H23F4N5ODegré de pureté :98.88%Couleur et forme :SolidMasse moléculaire :449.44LY3143921 hydrate
CAS :LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].Formule :C16H14FN5O2Degré de pureté :98.43%Couleur et forme :SolidMasse moléculaire :327.31Tanuxiciclib
CAS :Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.Formule :C15H13FN6OCouleur et forme :SolidMasse moléculaire :312.308GSK-3/CDK5/CDK2-IN-1
CAS :GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.433Tibremciclib
CAS :<p>Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].</p>Formule :C28H32F2N8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :518.6YK-2168
CAS :<p>YK-2168 is a differentiated selective inhibitor of CDK9.</p>Formule :C16H18ClN5Couleur et forme :SolidMasse moléculaire :315.80
